08:49 AM EDT, 05/28/2025 (MT Newswires) -- iTeos Therapeutics ( ITOS ) said Wednesday it intends to wind down operations after a strategic review of its development pipeline, business prospects, and financial position.

iTeos plans to focus on leveraging its cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of its intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, the company said.

iTeos shares were 24% higher in premarket trading.